AMGN - Amgen Inc
One of the original biotech pioneers, leveraging biologics expertise to build a portfolio in cardiovascular, oncology, and inflammation therapies.
Finlify Score
57.9 / 100
Data Quality
FULL
Penalty
0.0
Sector
Health Care
Close Price
$377.35
-1.34%
52W Range
$269.77 - $447.03
Market Cap
$232.4B
-1.3%Compared to previous day
2026 Q1 Revenue
$8.6B
-12.6%Changes from last reporting quarter
2026 Q1 EPS
$3.34
Diluted shares
Analyst Rating
43 analysts in latest ratings feed
RSI
18.8
<40 oversold
2Y Range Position
64%
-15.6% from high / +49.0% from low
Beta
0.47
Relative to market benchmark
MACD
-9.26
MACD line -1.75 / signal line 7.51
Fundamental Trend
Growth 43.0Financial Health
Quality 80.8Data Quality
FULLValuation Reference
Price Chart
Close price, two-year source window
Finlify Score
HOLD57.9 / 100
Score History
Finlify Score and component trend
Financial Statements
Calendar year view. Figures are estimates only. For official figures, refer to the company website.
| 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | |
|---|---|---|---|---|
| Revenue | $8.6B-12.6% | $9.9B+3.2% | $9.6B+4.1% | $9.2B+12.6% |
| Gross Profit | - | - | - | - |
| Operating Income | $2.7B-2.0% | $2.7B+7.7% | $2.5B-4.9% | $2.7B+125.5% |
| Net Income | $1.8B+36.5% | $1.3B-58.6% | $3.2B+124.6% | $1.4B-17.2% |
Columns use the calendar quarter of each reported period end date. QoQ is shown for adjacent company reporting quarters only.
AI Signal
Generated Aug 1, 2026
The Finlify signal for AMGN is HOLD, with an overall Finlify Score of 52.6/100, suggesting a neutral stance based on a comprehensive analysis of its components and full data quality.
Technical
Despite recent strong performance, with a 20-day return of 7.3% and a 60-day return of 19.7%, and being only -1.4% from its 52-week high, the Relative Strength score of 45.1/100 and Accumulation/Volume score of 46.3/100 appear below average. The RSI(14) of 67.4 also suggests the asset may be approaching overbought territory.
Fundamentals
While the Financial Quality score is robust at 80.8/100, the Fundamental Trend score of 43.0/100 indicates some potential concerns regarding recent fundamental momentum. Valuation multiples, such as a P/E of 26.8x and P/B of 20.4x, appear relatively high, though the asset does offer a 2.60% dividend yield and exhibits low volatility with a Beta of 0.4.
Macro Context
The prevailing macro environment, characterized by elevated inflation metrics like CPI at 3.7% and Core PCE at 3.3%, alongside a 10Y Treasury Yield of 4.7%, could present headwinds for growth-oriented assets. However, AMGN's low Beta of 0.4 may suggest some resilience against broader market volatility.
Key Risks
- Upcoming earnings on 2026-08-04 could introduce volatility.
- Valuation multiples (P/E 26.8x, P/B 20.4x) appear elevated, especially in light of a lower Fundamental Trend score of 43.0/100.
- Despite strong recent returns and being near its 52-week high, the asset's Relative Strength (45.1/100) and Accumulation/Volume (46.3/100) scores are below average, and the RSI of 67.4 suggests it may be approaching overbought conditions.